Organization

University of Utah

116 clinical trials

46 abstracts

9 posters

Abstract
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Org: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Pitié Salpêtrière Hospital, Duke University Medical Center,
Abstract
Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.
Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Vanderbilt University Medical Center, University of Utah, Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Merck & Co., Inc.,
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
Differential burnout by race, sex, and sexual orientation in academic oncology.
Org: University of Utah, Memorial Sloan Kettering Cancer Center, University of California San Francisco, Association of American Medical Colleges,
Abstract
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
Org: Duke Cancer Institute, University of California, San Francisco, University of Utah, University of California, Davis Comprehensive Cancer Center, University of Chicago Medicine,
Abstract
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,
Clinical trial
A Pilot Study of Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Metformin as a Novel, Mechanistic Treatment of Fibromyalgia; a Proof of Concept RCT
Status: Recruiting, Estimated PCD: 2025-12-31
Abstract
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
Org: Sarah Cannon Research Institute/Tennessee Oncology, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Royal Marsden NHS Foundation Trust, Lineberger Comprehensive Cancer Center,
Abstract
A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.
Org: Sarah Cannon Research Institute/Tennessee Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Duke University Medical Center, Huntsman Cancer Institute, University of Utah,
Abstract
Biological subgroups in melanoma: A correlation of tumor genomic and transcriptomic analysis with spatial immunophenotyping.
Org: School of Medicine, Zhejiang University, Hangzhou, China, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, Huntsman Cancer Institute at the University of Utah,
Abstract
Implementing a natural language processing pipeline to expedite clinical chart review to assess germline genetic testing in veterans with breast cancer.
Org: VA Salt Lake City Health Care, University of Utah, Durham VA Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, VHA National Oncology Program Office,
Clinical trial
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
Status: Terminated, Estimated PCD: 2022-08-20
Abstract
Real world outcomes in patients with follicular lymphoma treated with RCHOP vs BR.
Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Huntsman Cancer Institute/University of Utah, Hunstman Cancer Institute at the University of Utah,
Abstract
Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC).
Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Huntsman Cancer Institute at the University of Utah, University of Utah/Huntsman Cancer Institute,
Clinical trial
Pilot Study of Memantine for Enhanced Stroke Recovery
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Single-Dose Pharmacokinetics of Atropine Oral Gel in Healthy Adults
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Creatine for Treatment of Depression Associated With Type 2 Diabetes
Status: Withdrawn, Estimated PCD: 2024-06-10
Clinical trial
Remimazolam Safety and Efficacy for Nerve Blocks
Status: Completed, Estimated PCD: 2022-08-01
Clinical trial
Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Intradiscal Platelet-Rich Plasma Injection for Chronic Discogenic Low Back Pain
Status: Terminated, Estimated PCD: 2022-07-29
Clinical trial
Estradiol Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial
Status: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
Prospective Evaluation Analysis and Kinetics of IV Sotalol
Status: Completed, Estimated PCD: 2023-08-30
Clinical trial
HCI37833
Status: Completed, Estimated PCD: 2013-02-01
Clinical trial
A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
Status: Completed, Estimated PCD: 2022-06-11
Clinical trial
Use of Metformin to Improve Muscle Regrowth in Older Adults
Status: Not yet recruiting, Estimated PCD: 2029-07-31
Clinical trial
Metformin to Prevent Inactivity-induced Loss of Muscle Health During Aging
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
Impact of T Cells on Age-related Vascular Dysfunction: A Translational Approach
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
Status: Completed, Estimated PCD: 2019-06-30
Clinical trial
Effects of St. John's Wort on Levonorgestrel
Status: Completed, Estimated PCD: 2008-05-01
Clinical trial
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
Status: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
Neural and Antidepressant Effects of Propofol
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery
Status: Completed, Estimated PCD: 2023-01-31
Clinical trial
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
Status: Completed, Estimated PCD: 2020-06-09
Clinical trial
Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin
Status: Completed, Estimated PCD: 2019-06-30
Clinical trial
00061838
Status: Completed, Estimated PCD: 2016-11-01
Clinical trial
Implications for Management of PET Amyloid Classification Technology
Status: Completed, Estimated PCD: 2018-06-01
Clinical trial
Neurobiology of Non-Specific and Specific Treatment Responses in Major Depression
Status: Withdrawn, Estimated PCD: 2023-05-01
Clinical trial
LIA in Hip Arthroscopy Patients: An Extra-Capsular Approach
Status: Completed, Estimated PCD: 2020-03-01
Clinical trial
A Multi-modality Imaging Assessment of Chemobrain
Status: Completed, Estimated PCD: 2015-02-05
Clinical trial
Ketamine Assisted Psychotherapy for Opioid Use Disorder
Status: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-08-30
Clinical trial
Hydroxychloroquine for Outpatients With Confirmed COVID-19
Status: Completed, Estimated PCD: 2021-10-30
Abstract
Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
Org: Huntsman Cancer Institute at the University of Utah, University of Utah, Case Western Reserve University School of Medicine, University of Utah/Huntsman Cancer Institute,
Abstract
RT-PACE: Phase I/II study of adjuvant whole pelvic hypofractionated radiotherapy for non-metastatic cervical and endometrial cancer.
Org: University of Chicago, University of Utah, Hunstman Cancer Institute at the University of Utah, The University of Chicago Medicine Center for Advanced Care at Orland Park,
Abstract
Should I stay, or should I go? Factors associated with intent to leave academic oncology.
Org: University of California San Francisco, University of Utah, Dana-Farber Cancer Institute, Harvard Medical School, Memorial Sloan Kettering Cancer Center,
Abstract
Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study.
Org: Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Avera Cancer Institute, Sioux Falls, SD, The University of Arizona, Tucson, AZ, Huntsman Cancer Institute,
Abstract
Workplace sexual harassment in academic oncology.
Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Middletown, Association of American Medical Colleges, Alexandria, VA,
Abstract
Geographical impact on prostate cancer genetic testing eligibility: A preliminary study from an academic cancer center.
Org: University of Utah, Hunstman Cancer Institute at the University of Utah, Huntsman Cancer Institute,
Abstract
Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203.
Org: NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of California - Irvine, University of Florida Department of Health Outcomes and Biomedical Informatics, University of Oklahoma Health Sciences Center, Summa Health Medical Group,
Abstract
High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma.
Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Utah, Huntsman Cancer Institute, Intermountain Medical Center,
Abstract
A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.
Org: Vanderbilt University Medical Center, Hunstman Cancer Hospital, University of Utah Health, University of Utah, University of California Irvine, University of Pittsburgh Medical Center (UPMC),
Abstract
Differential tumor gene expression profiling of obese and non-obese patients (pts) with prostatic adenocarcinoma (PC).
Org: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, UTC Therapeutics, Huntsman Cancer Institute, University of Utah,
Abstract
Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.
Org: City of Hope National Medical Center, Vanderbilt-Ingram Cancer Center, VCU Massey Cancer Center, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute,
Abstract
The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.
Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Moffitt Cancer Center, Tampa, FL,
Abstract
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.
Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center,
Abstract
Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service.
Org: Durham VA Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, VA Salt Lake City Health Care, VHA National Oncology Program Office, University of Utah,
Abstract
Real-world treatment trends and outcomes in elderly patients with metastatic colorectal cancer in the United States.
Org: Cleveland Clinic Taussig Cancer Instititute, Huntsman Cancer Institute, University of Utah,
Abstract
Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).
Org: Huntsman Cancer Institute, University of Utah, Medical Oncology Group, Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology,
Abstract
Epidemiologic characteristics, treatment patterns, and survival analysis of plasmablastic lymphoma in the US.
Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Utah, Hunstman Cancer Institute at the University of Utah,
Abstract
Impact of synchronous (sync) vs metachronous (meta) metastasis at the presentation on survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs).
Org: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, UTC Therapeutics, Hunstman Cancer Institute at the University of Utah, City of Hope Comprehensive Cancer Center,
Abstract
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.
Org: University of Pennsylvania, NYU Langone Medical Center, Vanderbilt University Medical Center, University of Chicago, Division of Pulmonary and Critical Medicine, Department of Medicine, Mayo Clinic,
Abstract
Clinical characteristics of interval breast cancer within 12 months and 13-24 months in Utah.
Org: University of Utah, Intermountain Healthcare, Hunstman Cancer Institute at the University of Utah, University of Utah Division of Genetic Epidemiology,
Abstract
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.
Org: Institut de Cancérologie Gustave Roussy, Villejuif, France, France, Perlmutter Cancer Center at NYU Langone Health Medical Center, New York, NY,
Abstract
Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials.
Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, CLL Center, Dana-Farber Cancer Institute,
Abstract
Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases.
Org: Ann & Robert H. Lurie Children's Hospital, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Division of Pediatric Surgery, Medical College of Wisconsin, Department of Surgery, St. Jude Children's Research Hospital, Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital,
Abstract
Academic medical center access and outcomes in Kaposi sarcoma.
Org: Creighton University School of Medicine Phoenix Regional Campus, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Utah,
Abstract
Financial hardship among siblings of long-term survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS) report.
Org: Cancer and Blood Disorders Center, Seattle Children's Hospital, St. Jude Children's Research Hospital, CHOC Hem, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.
Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
Impact of disadvantaged socioeconomic and demographic status on survival in Kaposi sarcoma.
Org: Creighton University School of Medicine Phoenix Regional Campus, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Utah,
Abstract
Risk of inpatient and emergency department visits among lung cancer patients receiving immunotherapies as first line treatment: Findings from a linked population dataset.
Org: University of Utah, Johns Hopkins University Bloomberg School of Public Health, Huntsman Cancer Institute, Hunstman Cancer Institute at the University of Utah,
Abstract
Socioeconomic and demographic factors on academic center accessibility in sebaceous adenocarcinoma: An NCDB analysis.
Org: Creighton University School of Medicine Phoenix Regional Campus, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Utah,
Abstract
Examination of real-world data from geriatric assessments in a comprehensive cancer center to explore predominant and cancer-specific domains for intervention.
Org: University of Utah Hospital, Huntsman Cancer Institute, University of Utah, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Institute (NCI-CCC),